Comparison · NCT03126630-2ae78846
Group I (Pembrolizumab) vs Group II (Anetumab Ravtansine, Pembrolizumab): Phase 2 Progression Free Survival
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group I (Pembrolizumab) vs Group II (Anetumab Ravtansine, Pembrolizumab): Phase 2 Progression Free Survival. Trial comparisons, record NCT03126630-2ae78846. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03126630-2ae78846
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.588 | 0.36 | 0.784 | wilson | |
| Risk in group 2 | 0.5 | 0.29 | 0.71 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0882 | -0.222 | 0.375 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.18 | 0.64 | 2.16 | log | |
| Odds ratio, group 1 over group 2 | 1.43 | 0.375 | 5.44 | log | |
| Number needed to treat, for one more participant with the outcome on Group I (Pembrolizumab) than on Group II (Anetumab Ravtansine, Pembrolizumab) | 11.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group I (Pembrolizumab) | Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.\>~\>\>~\>~\>\> Laboratory Biomarker Analysis: Correlative studies\>~\>\>~\>~\>\> Pembrolizumab: Given IV\>~\>\>~\>~\>\> Pharmacological Study: Correlative studies | 10 | 17 | OG000 |
| Group 2 | Group II (Anetumab Ravtansine, Pembrolizumab) | Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.\> \>\>~\>~\>\> Anetumab Ravtansine: Given IV\>~\>\>~\>~\>\> Laboratory Biomarker Analysis: Correlative studies\>~\>\>~\>~\>\> Pembrolizumab: Given IV\>~\>\>~\>~\>\> Pharmacological Study: Correlative studies | 9 | 18 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Phase 2 Progression Free Survival
- Description
Will be estimated using the method of Kaplan-Meier. The comparison of progression-free survival between two treatment arms will be based on the log-rank test. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
- Time frame
- From the start of treatment to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
- NCT number
- NCT03126630
- Phases
- PHASE1, PHASE2
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2024-10-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03126630?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03126630-2ae78846